GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by ...

Spring has been bountiful at Cleveland's Abeona Therapeutics. | As Abeona gears up for the commercial rollout of Zevaskyn, ...

Gyroscope Therapeutics and its gene therapy for the sight-robbing disease ... which said it stands to make £334 million ($443 million) from the sale, a threefold return on its original £113 ...

The COVID-19 pandemic has bit into sales at Novartis ... Results also showed a strong launch for its rare diseases gene therapy, Zolgensma, which is now approved for the muscle wasting disease ...

Two excellent candidates are Vertex Pharmaceuticals ( VRTX -1.05%) and Axsome Therapeutics ( AXSM -1.06%). Here's what makes ...

News broke yesterday that researchers in Philadelphia appear to have successfully treated a 6-month-old baby boy, called KJ, ...

At the American Society of Cell and Gene Therapy conference, there were questions and qualms on how Vinay Prasad may change ...

The UNC technology, developed by Pediatrics Professor Chengwen Li, M.D., Ph.D., uses adeno-associated viruses (AAVs) to ferry ...

Biopharmas have been scaling back on AAV research for sometime now. Find out why and what's on the horizon for drug delivery ...

The Crispr therapy was tailored to the baby’s specific condition and could provide a template for others.

May 15, 2025 — A research team has developed and safely delivered a personalized gene editing therapy to treat an infant with a life-threatening, incurable genetic disease. The infant ...